Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
And a link to today RNS below...
https://www.londonstockexchange.com/news-article/POLB/immunomodulator-ii-patent-granted-in-japan/16217595
The Japanese Patent Office has agreed to grant the Immunomodulator II patent application for POLB 001, further strengthening their robust intellectual property in this territory. By continuing to strategically grow the IP around POLB 001 they aim to enhance the overall value of this exciting molecule for partnering purposes.
This latest patent relates to the pharmaceutical composition of POLB 001 for treating severe influenza in hospitalised patients in combination with antiviral compounds. They also received the fully granted Japanese patent for Immunomodulator I further to their announcement in September regarding same.
These guys are very excited (and rightly so!) by the potential of this asset to have a significant impact across multiple disease areas. As noted in our recent POLB 001 Update Meeting – there is very strong potential for this molecule in the rapidly growing field of cancer immunotherapies. These therapies are having a big impact on cancer but with challenges such as Cytokine Release Syndrome (CRS) affecting uptake, patient health and hospitalisation rates amongst others. An effective therapy for CRS could unlock the benefits of cancer immunotherapies, benefiting patients, healthcare systems and Big Pharma companies alike.
Https://twitter.com/PoolbegPharma/status/1726508831105274199
The snippet features a patient’s perspective & discusses Bob Munro’s journey.
Bob has entered remission after 12 years of treatment and highlights how these drugs seem to be game-changers for the world of cancer. However, he suffered many setbacks due the side effects associated with these breakthrough treatments and notes how CRS (Cytokine Release Syndrome) can massively impact a patient's journey and quality of life when dealing with cancer.
...and here is the #POLB RNS
https://www.londonstockexchange.com/news-article/POLB/polb-001-lps-trial-data-to-be-presented-at-iuis/16211943
Poolbeg abstract will be presented at the prestigious 18th International Congress of Immunology in Cape town later this month. The presentation will provide insight into the positive results from the POLB 001 LPS human challenge trial and its acceptance by IUIS truly underscores the potential of POLB 001 as a groundbreaking therapy for the Cytokine Release Syndrome (CRS) in oncology as well as severe influenza.
CRS is highly prevalent among patients receiving cancer immunotherapies. Severe cases of CRS are life-threatening and may require intensive care support. The positive data from the LPS challenge trial has highlighted that oral treatment of POLB 001 holds great promise in tackling this issue; potentially leading to decrease observed treatment side-effects, reduced strain on healthcare systems while making these treatments more readily accessible to a broader patient population.
The company seem very excited by the potential of POLB 001 in addressing this CRS related to cancer treatments which could unlock a further significant market for POLB 001.
Very interesting...
“…The company’s value has surged since it announced it was ramping up its operations earlier this month. Vinanz, with its low-cost, scalable model, powered by green energy, appears well placed to offer exposure to higher bitcoin prices…”
https://total-market-solutions.com/2023/11/vinanz-ltd/
“…the company is massively undervalued particularly in a great gold price environment…”
https://total-market-solutions.com/2023/11/chaarat-gold-holdings-ltd-nov-2023/
#POLB shared the full recording of Friday’s IMC presentation on Twitter:
https://twitter.com/PoolbegPharma/status/1723971941025841628
A number of key senior members of the former Amryt Pharma plc leadership team are joining Poolbeg Pharma.
Cathal Friel of course co-founded Amryt Pharma back in 2015 and floated it on AIM in 2016. Amryt went on to list on Nasdaq and earlier this year, was sold to Chiesi Farmaceutica for $1.48 billion. Cathal's ambition was always to create another billion-dollar biopharmaceutical company.
Excellent progress has been made at Poolbeg since IPO and now they plan to follow a similar strategic approach to Amryt which focused upon developing a number of very exciting clinical assets and the acquisition of approved and marketed drugs, which not only generate revenue but also fund the development of a robust pipeline of innovative products.
Joining Poolbeg is:
David Allmond, former Chief Business Officer at Amryt Pharma who was instrumental in putting in place the global commercial infrastructure in Amryt which supported its revenue growth from c. $1.5bn million when he joined in 2016, to close to US$250 million some six years later.
John McEvoy, former Global General Counsel at Amryt, led the acquisition of Aegerion Pharmaceuticals in 2019 and Chiasma Pharmaceuticals in 2021. He also led the company’s dual-listing on Nasdaq in 2020 and its subsequent sale to Chiesi in 2023.
Laura Maher was Associate Director of Clinical Operations at Amryt where she led the clinical research programmes for multiple products in Amryt’s pipeline including Filsuvez®, the world’s first approved epidermolysis bullosa treatment.
VERY exciting times...
https://www.londonstockexchange.com/news-article/POLB/former-amryt-pharma-leadership-team-join-poolbeg/16202153
“…With promising assets and solid operational and commercial progress, GMET may be set to light up a natural resources sector yet to emerge from the small cap market’s prevailing gloom…”
https://total-market-solutions.com/2023/11/golden-metal-resources-plc/
As you may know, on Monday Poolbeg Pharma hosted an Investor Meet Company presentation on the POLB 001 Oncology Programme Update.
The meeting was led by CEO Jeremy Skillington and featured presentations from a number of key opinion leaders and a patient advocate.
#POLB shared the full recording on out social media this morning:
https://twitter.com/PoolbegPharma/status/1722146941558276199
https://www.linkedin.com/posts/poolbeg-pharma_poolbeg-pharma-plc-polb-001-oncology-programme-activity-7127912675090554880-N7Qh?utm_source=share&utm_medium=member_desktop
“…Funding extensions shows Vast’s creditors want to be part of the growth path for the long term…”
Early stage exploration and development is an expensive business until the transition to production, break even and then cash flow positivity.
Vast Resources PLC has got the confidence and the backing of its lenders who are insiders of the business, who understand the strategy, the multi-region asset potential and perhaps recognise that cash flow positivity isn’t wishful thinking but a possibility.
This month’s debt funding update, says Chief Executive Andrew Prelea is a demonstration that creditors A&T Investments and Mercuria Energy Trading is “an indication of of them wanting to stick around and wanting to be part of the Vast growth path.”
Prelea highlights that the parties extending their warrants “shows their confidence in what we’re doing in our strategy in the foreseeable future” and could mean “they were still going to be around in another year or two.”
So what will the immediate future yield for creditors, warrant holders and shareholders alike?
“There are several things to take note of,” says Prelea who references production improvement at its Baita Plai Polymetallic Mine in Romania and updates on opportunities that the company has already shared in the public domain.
Watch Andrew talk to Sarah Lowther about the company doing what it said it was going to do in Romania, and how chatter concerning the repatriation of a historic package of diamonds may be undermining delicate negotiations surrounding their handover back to the company.
https://total-market-solutions.com/2023/11/vast-resources-plc-nov-2023/
Https://www.londonstockexchange.com/news-article/POLB/polb001-data-to-be-presented-at-ash-annual-meeting/16194560
Good news this!!
Poolbeg’s abstract will be presented at the prestigious 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego next month. The presentation will provide insight into the positive results from the POLB 001 LPS human challenge trial and its acceptance by ASH represents a strong validation of POLB 001’s potential in addressing Cytokine Release Syndrome (CRS) in oncology. CRS is highly prevalent among patients receiving cancer immunotherapies. Severe cases of CRS are life-threatening and may require intensive care support.
The positive data from the LPS challenge trial has highlighted that oral treatment of POLB 001 holds great promise in tackling this issue; potentially leading to decrease observed treatment side-effects, reduced strain on healthcare systems while making these treatments more readily accessible to a broader patient population.
The potential of POLB 001 in addressing this CRS related to cancer treatments which could unlock a further significant market for POLB 001. On Monday 6 November at 2pm Jeremy, alongside Prof Brendan Buckley, Multiple Myeloma clinician Dr Martin Kaiser, and Multiple Myeloma patient Bob Munro will be exploring the growing issue of managing CRS caused by cancer immunotherapy treatments and how POLB 001 could potentially solve this problem.
Poolbeg Pharma Driving forward R&D programmes while seeking partners
https://www.proactiveinvestors.co.uk/companies/news/1031798/poolbeg-pharma-driving-forward-r-amp-d-programmes-while-seeking-partners-1031798.html/long
“…there are grounds for suggesting that, at this price, VAST has entered value territory. Perhaps it is now possible to peer through the clouds to look again at a share that – at this price – may only have one way to go with solid operational progress and money in the bank…”
https://total-market-solutions.com/2023/11/vast-resources-plc-2/
“…It was very exciting announcing our lithium joint venture with Rio Tinto. Rio are definitely the operators and the managers on the ground…”
https://total-market-solutions.com/2023/10/aterian-plc-october-2023/
Https://www.londonstockexchange.com/news-article/POLB/sab-endorses-influenza-drug-targets/16182575
The #POLB Scientific Advisory Board have endorsed the drug targets identified from the companies AI-led drug discovery programme, the experts on our SAB were impressed with the outputs of the programme and a consensus was reached on the prioritized list of novel drug targets to bring forward for lab based validation, which is due to complete in 2024. They also provided valuable insight into how to most effectively validate the targets in line with the model.
The global interest in AI-led drug discovery continues to grow, with Big Pharma investing heavily in the space. This approach to drug discovery enables identification of targets faster, at lower cost, with reduced risk, and a higher likelihood of success. This approach combined with their unique human challenge trial data has resulted in some very exciting and novel drug targets, as well as unparalleled insights into human disease, which could transform the treatment of influenza for both seasonal and pandemic strains. They are continue to discuss the exciting outputs from our two AI-led drug discovery programmes with prospective partners.
#POLB featured in a @EPM_Magazine on "Could #AI save us from the next pandemic?", which highlights the advancements in technology & healthcare is aiding the future for #pandemic prevention.
Read article here:
https://pharmaceuticalmanufacturer.media/pharmaceutical-industry-insights/latest-pharmaceutical-manufacturing-industry-insights/could-ai-save-us-from-the-next-pandemic/